WHO International Standard
Second WHO International Standard for SARS-CoV-2 RNA
NIBSC code: 22/252
Instructions for use
(Version 1.0, Dated 24/10/2023)

1. INTENDED USE
The Second WHO International Standard for SARS-CoV-2 RNA for Nucleic acid Amplification Technique (NAT)-based assays consists of an acid-heat inactivated BetaCoV/Australia/VIC01/2020 isolate of SARS-CoV-2. The preparation has been evaluated in a WHO International Collaborative study, in parallel to the First WHO International Standard to which it is traceable [1]. The intended use of the International Standard is for the calibration and harmonisation of NAT-based assays or secondary reference reagents for the detection of SARS-CoV-2 RNA.

2. CAUTION
This preparation is not for administration to humans or animals in the human food chain.

The preparation contains material of human origin, and either the final product or the source materials, from which it is derived, have been tested and found negative for HBsAg, anti-HIV and HCV RNA. As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE
The assigned potency of the Standard, 22/252, is 7.50 Log10 IU/ampoule. After reconstitution in 0.5mL of molecular grade water or PBS, the final concentration of the preparation is 7.80 Log10 IU/mL.

4. CONTENTS
Country of origin of biological material: United Kingdom.
Each vial of 22/252 contains 0.5 mL of lyophilised, non-infectious, BetaCoV/Australia/VIC01/2020 isolate of SARS-CoV-2. The virus has been inactivated by treatment with acetic acid, followed by 1 hour incubation at 60°C and validated for inactivation by serial blind passage on permissive cells, with full details provided within the study report [1]. The material is formulated in universal buffer comprising 10 mM Tris-HCl (pH 7.4), 0.5% human serum albumin and 1% D-(-)-Trehalose dehydrate and contains a background of 1x10^5 copies/mL of human genomic DNA.

Variants were called against the Wuhan-1 reference sequence (Genbank accession number NC_045512.2) using iVar and lofreq variant callers as part of a bioinformatic pipeline developed in-house [1]. Mutations with a proportion >5% of the population are listed:

<table>
<thead>
<tr>
<th>Position (NC_045512.2)</th>
<th>Ref</th>
<th>Alt</th>
<th>Depth</th>
<th>SNP/indel</th>
<th>Syn/NonSyn</th>
<th>Proportion</th>
<th>Gene</th>
</tr>
</thead>
<tbody>
<tr>
<td>19065</td>
<td>T</td>
<td>C</td>
<td>37464</td>
<td>SNP</td>
<td>Syn</td>
<td>0.9992</td>
<td>ORF1ab</td>
</tr>
<tr>
<td>22303</td>
<td>T</td>
<td>G</td>
<td>113805</td>
<td>SNP</td>
<td>Ser-&gt;Asp</td>
<td>0.9995</td>
<td>S</td>
</tr>
<tr>
<td>26144</td>
<td>G</td>
<td>T</td>
<td>28985</td>
<td>SNP</td>
<td>Gly-&gt;Val</td>
<td>0.988</td>
<td>ORF3a</td>
</tr>
<tr>
<td>29749</td>
<td>A</td>
<td>C</td>
<td>17751</td>
<td>deletion</td>
<td>N/A</td>
<td>0.9834</td>
<td>ORF10/CHR,EN</td>
</tr>
</tbody>
</table>

5. STORAGE
The ampoules should be stored at -20°C or below until use. Please note because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING
DIN ampoules have an ‘easy-open’ coloured stress point, where the narrow ampoule stem joins the wider ampoule body. Various types of ampoule breaker are available commercially. To open the ampoule, tap the ampoule gently to collect material at the bottom (labelled) end and follow manufacturers instructions provided with the ampoule breaker.

7. USE OF MATERIAL
No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution.

The material should be reconstituted in 0.5 mL of molecular grade water or PBS. Following addition, the ampoule should be left at ambient temperature for 20 minutes and then mixed thoroughly, avoiding generation of excess foam. Once reconstituted, 22/252 should be diluted in the matrix appropriate to the material/assay being calibrated and requires extraction prior to SARS-CoV-2 RNA measurement.

8. STABILITY
Reference materials are held at NIBSC within assured, temperature-controlled storage facilities. Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to their reference materials. It is the policy of WHO not to assign an expiry date to their international reference materials. They remain valid with the assigned potency and status until withdrawn or amended.

9. REFERENCES

10. ACKNOWLEDGEMENTS
We gratefully acknowledge the important contributions of the WHO collaborative study participants. We express our thanks to Victoria Infectious Diseases Reference Laboratory, Royal Melbourne Hospital (Australia) for the provision of the BetaCoV/Australia/VIC01/2020 isolate.

11. FURTHER INFORMATION
Further information can be obtained as follows;
This material: enquiries@nibsc.org
WHO Biological Standards: http://www.who.int/biologicals/en/
Derivation of International Units: http://www.nibsc.org/standardisation/international_standards.aspx
NIBSC Terms & Conditions: http://www.nibsc.org/terms_and_conditions.aspx
12. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION
In all publications, including data sheets, in which this material is referenced, it is important that the preparation’s title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET
Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical appearance:</strong> White powder</td>
<td><strong>Corrosive:</strong> No</td>
</tr>
<tr>
<td><strong>Stable:</strong> Yes</td>
<td><strong>Oxidising:</strong> No</td>
</tr>
<tr>
<td><strong>Hygroscopic:</strong> No</td>
<td><strong>Irritant:</strong> No</td>
</tr>
<tr>
<td><strong>Flammable:</strong> No</td>
<td><strong>Handling:</strong> See caution, Section 2</td>
</tr>
<tr>
<td><strong>Other (specify):</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Toxicological properties**
- Effects of inhalation: Not established, avoid inhalation
- Effects of ingestion: Not established, avoid ingestion
- Effects of skin absorption: Not established, avoid contact with skin

**Suggested First Aid**
- **Inhalation:** Seek medical advice
- **Ingestion:** Seek medical advice
- **Contact with eyes:** Wash with copious amounts of water. Seek medical advice
- **Contact with skin:** Wash thoroughly with water.

**Action on Spillage and Method of Disposal**
Spillage of ampoule contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

15. LIABILITY AND LOSS
In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents. Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) (“Conditions”) apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. INFORMATION FOR CUSTOMS USE ONLY

<table>
<thead>
<tr>
<th>Country of origin for customs purposes*: United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.</td>
</tr>
<tr>
<td><strong>Net weight:</strong> 0.5g</td>
</tr>
<tr>
<td><strong>Toxicity Statement:</strong> Toxicity not assessed</td>
</tr>
<tr>
<td><strong>Veterinary certificate or other statement if applicable.</strong></td>
</tr>
<tr>
<td><strong>Attached:</strong> No</td>
</tr>
</tbody>
</table>

17. CERTIFICATE OF ANALYSIS
NIBSC does not provide a Certificate of Analysis for WHO Biological Reference Materials because they are internationally recognised primary reference materials fully described in the instructions for use. The reference materials are established according to the WHO Recommendations for the preparation, characterization and establishment of international and other biological reference standards http://www.who.int/bloodproducts/publications/TRS932Annex2_Inter_biolefstandardsrev2004.pdf (revised 2004). They are officially endorsed by the WHO Expert Committee on Biological Standardization (ECBS) based on the report of the international collaborative study which established their suitability for the intended use.